Stock Financial Ratios, Dividends, Split History

AMD / Advanced Micro Devices, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price12.98
Volume43,267,000.00
Market Cap ($M)12,579.05
Enterprise Value ($M)12,789.05
Book Value / Share0.63
Price / Book20.60
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Diluted Shares Outstanding Adjustment 87,000,000
Weighted Average Number Of Diluted Shares Outstanding 1,039,000,000
Common Shares Outstanding 969,110,191
Common Stock Shares Outstanding 967,000,000
Weighted Average Number Of Shares Outstanding Basic 952,000,000
Scoring Models
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.01
Return on Equity (ROE)0.10
Balance Sheet (mrq) ($M)
Assets3,540.00
Liabilities2,929.00
Quick Ratio1.27
Current Ratio1.76
Income Statement (mra) ($M)
Sales Revenue Net5,329,000,000.00
Operating Income204.00
Net Income43.00
Earnings Per Share Basic0.04
Earnings Per Share Diluted0.04
Cash Flow Statement (mra) ($M)
Cash From Operations68.00
Cash from Investing-114.00
Cash from Financing-114.00
Identifiers and Descriptors
CUSIP007903107
Central Index Key (CIK)2488
Related CUSIPS
007903907 007903958 007903957 007903909

Split History

Stock splits are used by Advanced Micro Devices, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
AMD: Advanced Micro Devices Stock Analysis and Research Report

2017-09-28 - Asif

We are a global semiconductor company with facilities around the world. Within the global semiconductor industry, we offer primarily: x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs) and professional graphics processors; and server and embedded processors, semi-custom System-on-Chip (SoC) products and technology for game consoles. We also license portions of our intellectual property portfolio. In this section, we will describe the general financial condition and the results of operations of Advanced Micro Devices, Inc. and its wholly-owned subsidiaries (collectively, “us,” “our” or “AMD”), including a discussion of our results of operations for the quarter and six months ended July 1, 2017 compared to the quarter and six months ended June 25, 2016 , an analysis of changes in our financial condition and a discussion of our contractual obligations. We believe our fin...

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

5 Top Stock Trades for Friday Morning

2018-05-25 investorplace
President Trump decided to pull out of his meeting with North Korean leader Kim Jong Un and that’s left stocks under pressure. Here’s our top stock trades as a result. (683-1)

Buy Micron (MU) Stock For Value & Growth Outlook

2018-05-23 zacks
Shares of Micron (MU - Free Report) opened lower on Wednesday after two days of gains on the back of some major announcements, including a new deal with Intel (INTC - Free Report) . With that said, let’s dive into why the chip giant’s stock might be worth buying right now. (784-1)

Cowen’s Price Target for Nvidia Corporation Isn’t So Crazy

2018-05-23 investorplace
With nothing more than a quick glance at the headlines, one might conclude it’s just another case of the analyst community playing a game of “chicken,” with NVIDIA Corporation (NASDAQ:NVDA) serving as the proverbial guinea pig. The game? Who’s willing to set the highest target price for NVDA stock. (791-3)

Assessing The AMD Battleground From All Sides

2018-05-23 seekingalpha
There's still a lot of investor interest and passion surrounding the stock, and its future prospects are not yet clear. (897-0)

Intel, Google & Microsoft Discover New Low-Risk Chip Flaws

2018-05-23 zacks
Intel (INTC - Free Report) , Alphabet’s (GOOGL - Free Report) Google and Microsoft (MSFT - Free Report) recently revealed two new security bugs, namely Speculative Store Buffer Bypass or Variant 4 and Rogue System Registry Read. (714-0)

CUSIP: 007903107